Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.
CAS PubMed PubMed Central Article Google Scholar
Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565–75.
CAS PubMed Article Google Scholar
Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250–60.
Zoellner AK, Unterhalt M, Stilgenbauer S, Hübel K, Thieblemont C, Metzner B, et al. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2021;8(9):e648–57.
Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105(7):2677–84.
CAS PubMed Article Google Scholar
Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, et al. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY. Cancer Sci. 2018;109(9):2830–40.
CAS PubMed PubMed Central Article Google Scholar
Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, et al. 15-year follow-up of the second nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175(3):410–8.
CAS PubMed Article Google Scholar
Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton’s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol. 2013;31(1):128–30.
CAS PubMed Article Google Scholar
Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122(10):3416–23.
CAS PubMed PubMed Central Article Google Scholar
Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 2013;12(3):229–43.
CAS PubMed PubMed Central Article Google Scholar
Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol. 2012;31(2):119–32.
CAS PubMed Article Google Scholar
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.
CAS PubMed PubMed Central Article Google Scholar
Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019;104(5):e211-e4.
Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179(3):430–8.
CAS PubMed PubMed Central Article Google Scholar
Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559–63.
CAS PubMed Article Google Scholar
Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183(4):578–87.
CAS PubMed Article Google Scholar
Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, et al. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a “real world” study. Hematol Oncol. 2017;35(4):528–35.
CAS PubMed Article Google Scholar
Shah B, Zhao X, Silva AS, Shain KH, Tao J. Resistance to Ibrutinib in B cell malignancies: one size does not fit all. Trends Cancer. 2018;4(3):197–206.
CAS PubMed Article Google Scholar
Roué G, Sola B. Management of drug resistance in mantle cell lymphoma. Cancers (Basel). 2020;12(6):1565.
Hershkovitz-Rokah O, Pulver D, Lenz G, Shpilberg O. Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects. Br J Haematol. 2018;181(3):306–19.
CAS PubMed Article Google Scholar
George B, Chowdhury SM, Hart A, Sircar A, Singh SK, Nath UK, et al. Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas. Cancers (Basel). 2020;12(5).
Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26(6):1175–9.
CAS PubMed Article Google Scholar
Weaver JA, Peng Y, Ji Y, Gilbertson D, Pease DF, Morrison VA. A medicare database analysis of practice patterns in patients with mantle cell lymphoma. J Geriatr Oncol. 2021;12(6):894–901.
CAS PubMed Article Google Scholar
Goyal RK, Jain P, Nagar SP, Le H, Kabadi SM, Davis K, et al. Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma. Leuk Lymphoma. 2021;62(6):1325–34.
CAS PubMed Article Google Scholar
Sharman J, Kabadi SM, Clark J, Andorsky D. Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study. Br J Haematol. 2021;192(4):737–46.
CAS PubMed Article Google Scholar
Izutsu K, Suzumiya J, Takizawa J, Fukase K, Nakamura M, Jinushi M, et al. Real world treatment practices for mantle cell lymphoma in Japan: an observational database research study (CLIMBER-DBR). J Clin Exp Hematop. 2021;61(3):135–44.
PubMed PubMed Central Article Google Scholar
Wade DT, Collin C. The Barthel ADL Index: a standard measure of physical disability? Int Disabil Stud. 1988;10(2):64–7.
CAS PubMed Article Google Scholar
Okamoto M, Kusumoto S. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-4. Mantle cell lymphoma (MCL). Int J Hematol. 2020;111(1):5–15.
Zelenetz AD, Gordon LI, Chang JE, et al. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Netw. 2021;19(11):1218–1230.
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.
Paydas S. Management of adverse effects/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019;136:56–63.
National Comprehensive Cancer Network (NCCN) Guidelines for Patients. Mantle Cell Lymhoma. 2021. Available at https://www.nccn.org/patients/guidelines/content/PDF/Mantle-patient-guideline.pdf.
Kabadi SM, Near A, Wada K, Burudpakdee C. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States. Cancer Med. 2019;8(17):7174–85.
CAS PubMed PubMed Central Article Google Scholar
Sharman J, Kabadi SM, Clark J, Andorsky D. Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study. Br J Haematol. 2021;192(4):737–46.
CAS PubMed Article Google Scholar
Ghosh N, Emond B, Lafeuille MH, Côté-Sergent A, Lefebvre P, Huang Q. Treatment patterns among patients with mantle cell lymphoma and comparison of healthcare resource utilization and costs among relapsed/refractory patients treated with ibrutinib or chemoimmunotherapy: a real-world retrospective study. Clin Ther. 2021;43(8):1285–99.
CAS PubMed Article Google Scholar
McCulloch R, Lewis D, Crosbie N, Eyre TA, Bolam S, Arasaretnam A, et al. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. Br J Haematol. 2021;193(2):290–8.
CAS PubMed Article Google Scholar
Abrahamsson A, Albertsson-Lindblad A, Brown PN, Baumgartner-Wennerholm S, Pedersen LM, D’Amore F, et al. Real world data on primary treatment for mantle cell lymphoma: a nordic lymphoma group observational study. Blood. 2014;124(8):1288–95.
CAS PubMed Article Google Scholar
Pfreundschuh M. Age and sex in non-hodgkin lymphoma therapy: it’s not all created equal, or is it? Am Soc Clin Oncol Educ Book. 2017;37:505–11.
Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, et al. Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. Am J Hematol. 2021;96(11):1374–84.
CAS PubMed PubMed Central Article Google Scholar
Rampotas A, Wilson MR, Lomas O, Denny N, Leary H, Ferguson G, et al. Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: a UK and Ireland analysis. Br J Haematol. 2021;194(2):365–77.
留言 (0)